CTOs on the Move

Kinerase

www.kinerase.com

 
Kinerase is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinerase.com
  • 1 Enterprise Kinerase Support
    Aliso Viejo, CA USA 92656
  • Phone: 800.321.4576

Executives

Name Title Contact Details

Similar Companies

Found

Found is a modern weight care platform pioneering integrated support through personalized coaching, online community, and if indicated, prescription medication. We believe that weight care is complex and goes beyond having the willpower to eat less and move more. We believe in the power of biology, genetics, sleep, stress, mental health and daily habits and we work with each factor to achieve long-lasting results. Our goals are to address the long-term risks associated with ineffective weight management, to reimagine the narrow and outdated cultural narrative around weight, and to empower our community with tools that will help them find self-acceptance and add years to their lives. We believe it`s not just what you`ve lost, it`s what you`ve Found.

Strategic Healthcare Programs

Strategic Healthcare Programs is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Martech Medical Products

Martech Medical Products is a Harleysville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AxioMed Spine Corporation

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.